Compare BALL & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BALL | DVA |
|---|---|---|
| Founded | 1880 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 14.9B |
| IPO Year | 2009 | 2003 |
| Metric | BALL | DVA |
|---|---|---|
| Price | $63.95 | $187.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 8 |
| Target Price | $71.57 | ★ $219.86 |
| AVG Volume (30 Days) | ★ 2.1M | 477.7K |
| Earning Date | 11-03-2026 | 11-02-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.59 | ★ 6.86 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $13.36 | $3.77 |
| Revenue Next Year | $4.21 | $3.39 |
| P/E Ratio | $39.75 | ★ $27.21 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $44.83 | $101.00 |
| 52 Week High | $68.56 | $247.49 |
| Indicator | BALL | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 72.90 | 56.63 |
| Support Level | $60.25 | $186.61 |
| Resistance Level | $63.99 | $202.63 |
| Average True Range (ATR) | 1.24 | 3.82 |
| MACD | 0.89 | 1.44 |
| Stochastic Oscillator | 93.96 | 79.67 |
Ball is the world's largest metal can manufacturer with market share over 30% in its three main regions (North America, Europe, and South America). The company is focused on increasing capacity amid a wave of new developed-market demand, while also investing in faster-growing emerging-market economies. Ball spun-off its glass jar business in 1993 and is now owned by Newell. The company reports three segments—beverage packaging, North and Central America (48% of 2025 revenue), beverage packaging, EMEA (30%), beverage packaging, South America (16%)—and it generated $13 billion in revenue in 2025.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.